The Tall one's links are always very interesting.
I had IGRT by IMRT, an external beam only treatment, with neoadjuvant and ongoing ADT (3 year sentence). My Vanderbilt University RO (Nashville, TN) was not a big proponent of the triple-play combo RT HDR/EBRT/HT, preferring the capability of their Varian Trilogy with RapidArc IMRT machine's accuracy in attaining similar results without the added complications of HDR brachytherapy. At 16 months post-diagnosis, one year post-RT, and ongoing ADT, my PSA is still undetectable so I'm guardedly optimistic.
Interesting in the article itself, the Japanese researchers did not find their combo therapy method any more successful than the EBRT and ADT combo. They're not sure, but they think in part their great outcome with both methods may be due to some genetic factors.
Hiromichi ISHIYAMA1 et al said...
However, our outcomes may be attributable to
Japanese-specific high-sensitivity to hormonal therapy.
***agai et al. [26] reported that Japanese–American men
showed significantly better outcomes than Caucasian men
for overall and cause-specific survival rates after hormonal
therapy. Table 3 shows selected Japanese series of high-risk
prostate cancer patients treated with conventional EBRT and
hormonal therapy [27–31]. These favorable outcomes of conventional
EBRT seem to be equal to our HDR approach.
From the data of the 5-year follow up, our tri-modality
therapy did not show any advantages over conventional
EBRT with hormonal therapy.
The vociferous support on this forum for the "combo" RT modality has caused some consternation for me, and I've had some fairly lengthy discussions with my RO at Vandy about
this in particular. People here really pushed it, and thus I was relatively demanding about
it with my RO before my treatment series.
If it's so obviously superior, why wasn't Vandy offering it? He said they certainly have the capability and the equipment, but have not seen it to be demonstrably worth the potential additional side effects and complications. They're a referral center for those dealing with complications from RT elsewhere, usually urinary strictures, and thus may be a little gun-shy about
adopting the procedure.
Hypofractionation seems even more interesting, since to this day there isn't agreement about
the alpha/beta ratio of prostate tissue. My RO says this is still a debated topic without consensus. The SBRT modality, if it can be shown to work for very high risk cases, seems really attractive. It doesn't seem the studies are there yet to support it in those cases.
Jerry